Clinical trial · Observational
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study
NCT07657299CI-TRIAL-00115315completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC. With evidence of E-cadherin, β-catenin and SOX4 playing a role in the development of tumors, it manifests as invasion and metastasis. In this study, we hope to develop the correlation regarding the alternation in the expression of E-cadherin, β-catenin and Sox4 in determining the recurrence, progression and up staging and their prognostic value in NMIBC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Bladder Cancer Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- 30 patients who treated with transurethral resection of bladder tumor finally diagnosed with NMIBC
- description
- * Inclusion Criteria: 1. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination. 2. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination * Exclusion Criteria: 1. Age at the time of cancer diagnosis \> 70 years 2. Patients diagnosed with MIBC 3. Patients with concomitant upper urinary tracts tumors 4. Patients with concomitant prostatic tumors 5. Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG 6. Patients showed BCG toxicity signs 7. Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT 8. Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC; * Bladder exstrophy. * Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants,
Primary outcomes (1)
- measure
- This study aims to develop correlation regarding the alternation in the expression of E-cadherin, β-catenin and SOX4 in determining the recurrence and/or progression and their prognostic value in NMIBC TCC.
- timeFrame
- 2 years
- description
- This study aims to develop correlation regarding the alternation in the expression of E-cadherin, β-catenin and SOX4 in determining the recurrence and/or progression and their prognostic value in NMIBC TCC.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: 1\. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination. 2\. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination \- Exclusion Criteria: 1. Age at the time of cancer diagnosis \> 70 years 2. Patients diagnosed with MIBC 3. Patients with concomitant upper urinary tracts tumors 4. Patients with concomitant prostatic tumors 5. Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG 6. Patients showed BCG toxicity signs 7. Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT 8. Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC; * Bladder exstrophy. * Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants, and may increase your bladder cancer risks. * Cowden disease: This syndrome, linked to an abnormal form of the gene PTEN, may trigger breast cancer and thyroid cancer, and increases the risk of bladder cancer. * Lynch syndrome: This genetic condition, also known as hereditary non-polyposis colorectal cancer, is usually tied to colon and endometrial cancer. However, this syndrome may also increase the risk of bladder cancer and cancer of the ureter. 9. Patients with history of chemotherapy or pelvic radiations for other tumor treatment than BC
References
Publications (20)
- BACKGROUNDDu Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood. 2005 Oct 1;106(7):2498-505. doi: 10.1182/blood-2004-12-4840. Epub 2005 Jun 16. PMID 15961513
- BACKGROUNDChan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21. doi: 10.1073/pnas.0906549106. Epub 2009 Aug 4. PMID 19666525
- BACKGROUNDOjha R, Singh SK, Bhattacharyya S, Dhanda RS, Rakha A, Mandal AK, Jha V. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent. J Urol. 2014 Jun;191(6):1889-98. doi: 10.1016/j.juro.2014.01.006. Epub 2014 Jan 15. PMID 24440234
- BACKGROUNDTiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 2013 Jun 10;23(6):768-83. doi: 10.1016/j.ccr.2013.04.020. PMID 23764001
- BACKGROUNDLioubinski O, Muller M, Wegner M, Sander M. Expression of Sox transcription factors in the developing mouse pancreas. Dev Dyn. 2003 Jul;227(3):402-8. doi: 10.1002/dvdy.10311. PMID 12815626
- BACKGROUNDYilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009 Jun;28(1-2):15-33. doi: 10.1007/s10555-008-9169-0. PMID 19169796
- BACKGROUNDKashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol. 2007 Sep;14(9):789-94. doi: 10.1111/j.1442-2042.2007.01830.x.